Brainsway (NASDAQ:BWAY) Sets New 12-Month High – Should You Buy?
by Michael Walen · The Markets DailyShares of Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY – Get Free Report) hit a new 52-week high during trading on Friday . The company traded as high as $16.43 and last traded at $16.4940, with a volume of 1561 shares traded. The stock had previously closed at $15.75.
Wall Street Analysts Forecast Growth
A number of analysts have recently commented on BWAY shares. Northland Securities set a $15.00 price objective on shares of Brainsway in a research report on Thursday, January 22nd. Weiss Ratings reissued a “hold (c-)” rating on shares of Brainsway in a research report on Monday, December 29th. HC Wainwright cut their price objective on shares of Brainsway from $30.00 to $15.00 and set a “buy” rating on the stock in a research report on Thursday, March 12th. Wall Street Zen raised shares of Brainsway from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. Finally, Zacks Research raised shares of Brainsway from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 24th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $15.00.
Check Out Our Latest Analysis on BWAY
Brainsway Price Performance
The company has a market capitalization of $659.33 million, a P/E ratio of 66.00 and a beta of 1.10. The company’s 50-day moving average price is $13.58 and its two-hundred day moving average price is $10.80.
Brainsway (NASDAQ:BWAY – Get Free Report) last issued its quarterly earnings data on Wednesday, March 11th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.03. The company had revenue of $14.55 million for the quarter, compared to analyst estimates of $14.02 million. Brainsway had a net margin of 14.62% and a return on equity of 11.10%. On average, analysts anticipate that Brainsway Ltd. Sponsored ADR will post 0.31 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Brainsway
Several institutional investors and hedge funds have recently modified their holdings of BWAY. Essex Investment Management Co. LLC grew its stake in Brainsway by 3.2% during the third quarter. Essex Investment Management Co. LLC now owns 310,684 shares of the company’s stock worth $4,682,000 after buying an additional 9,744 shares in the last quarter. ARK Investment Management LLC acquired a new stake in Brainsway during the fourth quarter worth about $2,422,000. Y.D. More Investments Ltd grew its stake in Brainsway by 559.8% during the fourth quarter. Y.D. More Investments Ltd now owns 114,962 shares of the company’s stock worth $2,187,000 after buying an additional 97,537 shares in the last quarter. Two Sigma Investments LP grew its stake in Brainsway by 25.2% during the third quarter. Two Sigma Investments LP now owns 102,902 shares of the company’s stock worth $1,551,000 after buying an additional 20,706 shares in the last quarter. Finally, Legato Capital Management LLC grew its stake in Brainsway by 9.3% during the fourth quarter. Legato Capital Management LLC now owns 97,376 shares of the company’s stock worth $1,852,000 after buying an additional 8,295 shares in the last quarter. 30.11% of the stock is currently owned by institutional investors and hedge funds.
About Brainsway
Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.
The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.